These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 18468682)

  • 1. Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: increased frequency of other cancers and of cancers in multiple family members.
    Padmanabhan A; Baker JA; Zirpoli G; Sait SN; Ford LA; Moysich KB; Baer MR
    Leuk Res; 2008 Dec; 32(12):1820-3. PubMed ID: 18468682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
    J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
    Patt DA; Duan Z; Fang S; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2007 Sep; 25(25):3871-6. PubMed ID: 17664457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemia incidence following primary breast carcinoma treatment.
    Kaplan HG; Malmgren JA; Atwood M
    Cancer; 2004 Oct; 101(7):1529-36. PubMed ID: 15378478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: a population-based study.
    Kaplan H; Malmgren J; De Roos AJ
    Breast Cancer Res Treat; 2013 Feb; 137(3):863-7. PubMed ID: 23274844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
    Praga C; Bergh J; Bliss J; Bonneterre J; Cesana B; Coombes RC; Fargeot P; Folin A; Fumoleau P; Giuliani R; Kerbrat P; Hery M; Nilsson J; Onida F; Piccart M; Shepherd L; Therasse P; Wils J; Rogers D
    J Clin Oncol; 2005 Jun; 23(18):4179-91. PubMed ID: 15961765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.
    Saso R; Kulkarni S; Mitchell P; Treleaven J; Swansbury GJ; Mehta J; Powles R; Ashley S; Kuan A; Powles T
    Br J Cancer; 2000 Jul; 83(1):91-4. PubMed ID: 10883674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.
    Kaplan HG; Malmgren JA; Li CI; Calip GS
    Breast Cancer Res Treat; 2013 Dec; 142(3):629-36. PubMed ID: 24265034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and susceptibility to therapy-related myeloid neoplasms.
    Leone G; Fianchi L; Pagano L; Voso MT
    Chem Biol Interact; 2010 Mar; 184(1-2):39-45. PubMed ID: 20026017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
    Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
    J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
    Swolin B; Rödjer S; Westin J
    Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
    Freedman RA; Seisler DK; Foster JC; Sloan JA; Lafky JM; Kimmick GG; Hurria A; Cohen HJ; Winer EP; Hudis CA; Partridge AH; Carey LA; Jatoi A; Klepin HD; Citron M; Berry DA; Shulman LN; Buzdar AU; Suman VJ; Muss HB
    Breast Cancer Res Treat; 2017 Jan; 161(2):363-373. PubMed ID: 27866278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Warren JL; Brown ML
    J Natl Cancer Inst; 2007 Jul; 99(13):1050; author reply 1051-2. PubMed ID: 17596580
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Clavarezza M; Del Mastro L; Pronzato P; Bruzzi P; Venturini M
    J Natl Cancer Inst; 2007 Jul; 99(13):1050-1; author reply 1051-2. PubMed ID: 17596581
    [No Abstract]   [Full Text] [Related]  

  • 16. Is family history of breast cancer a marker of susceptibility to exposures in the incidence of de novo adult acute leukemia?
    Rauscher GH; Sandler DP; Poole C; Pankow J; Shore D; Bloomfield CD; Olshan AF
    Cancer Epidemiol Biomarkers Prev; 2003 Apr; 12(4):289-94. PubMed ID: 12692102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
    Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
    Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
    Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
    Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why is there so much therapy-related AML and MDS and so little therapy-related CML?
    Gale RP; Hlatky L; Sachs RK; Radivoyevitch T
    Leuk Res; 2014 Oct; 38(10):1162-4. PubMed ID: 25175829
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia.
    Robertson LE; Estey E; Kantarjian H; Koller C; O'Brien S; Brown B; Keating MJ
    Leukemia; 1994 Dec; 8(12):2047-51. PubMed ID: 7807993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.